{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-108447","form_type":"8-K","ticker":"VIVS","cik":"0001497253","company_name":"VivoSim Labs, INC.","filed_at":"2025-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.120033+00:00","generated_at":"2026-05-17T13:06:20.561822+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"VivoSim Labs appoints Tony Lialin as Chief Commercial Officer","bullets":["Tony Lialin appointed CCO effective Aug 11, 2025; leads go-to-market strategy for NAMkind liver/intestine 3D models.","Annual salary $360,000, sign-on bonus $10,000, target bonus up to 40% of base salary.","Granted option to purchase 40,000 shares vesting over 4 years (25% cliff at 1 yr, then quarterly).","Company cites global liver/GI in-vitro market at $641M in 2024, U.S. share 50.8% ($325M)."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-108447","json":"https://secwatch.observer/filing/0000950170-25-108447.json","markdown":"https://secwatch.observer/filing/0000950170-25-108447.md","text":"https://secwatch.observer/filing/0000950170-25-108447.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1497253/000095017025108447/0000950170-25-108447-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1497253/000095017025108447/vivs-20250814.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T13:06:20.561822+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}